Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases
Open accessThe DOI matches its Crossref record; 307 of the 310 references it cites were found in a registry or an index.
Abstract
Neurodegeneration is a chronic progressive loss of neuronal cells leading to deterioration of central nervous system (CNS) functionality. It has been shown that neuroinflammation precedes neurodegeneration in various neurodegenerative diseases. Matrix metalloproteinases (MMPs), a protein family of zinc‐containing endopeptidases, are essential in (neuro)inflammation and might be involved in neurodegeneration. Although MMPs are indispensable for physiological development and functioning of the organism, they are often referred to as double‐edged swords due to their ability to also inflict substantial damage in various pathological conditions. MMP activity is strictly controlled, and its dysregulation leads to a variety of pathologies. Investigation of their potential use as therapeutic targets requires a better understanding of their contributions to the development of neurodegenerative diseases. Here, we review MMPs and their roles in neurodegenerative diseases: Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD), and multiple sclerosis (MS). We also discuss MMP inhibition as a possible therapeutic strategy to treat neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MMP-1, cleaves the structural connective tissue components collagen type I, II and II, and is detected only at low levels under physiological conditions, but can be abnormally high in several age-associated pathologies”
From Redox control of senescence and age-related disease. (2017) · cites this paper as [137]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the association between MMP-1 and ROS and the significance of these interactions in degenerative disease etiology is well established”
From Redox control of senescence and age-related disease. (2017) · cites this paper as [137]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polazzi, E., Mengoni, I., Caprini, M., Peña-Altamira, E., Kurtys, E., & Monti, B. (2013) · Neurosignals · doi:10.1159/000337115 · Cited by 8,994
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576 · cited 1×
“Additionally, ALS is associated with protein inclusions composed mostly of transactive response DNAbinding protein 43 (TDP-43) in the cytoplasm in the affected areas of the brain and spinal cord [232].”
Background2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Visse, R., & Nagase, H. (2003) · Circulation Research · doi:10.1161/01.res.0000070112.80711.3d · Cited by 4,575 · cited 1×
“of MMPs), catalytic domain (holds the Zn ion), hinge region (connecting sequences), and C-terminal hemopexinlike domain (required for substrate and TIMP recognition) [6] (Figure 1).”
Microglia: a sensor for pathological events in the CNS
Kreutzberg, G. W. (1996) · Trends in Neurosciences · doi:10.1016/0166-2236(96)10049-7 · Cited by 4,396 · cited 1×
“When triggered by various immunological stimuli, microglia morphologically transform into ameboid cells and start to proliferate and secrete inflammatory mediators [109, 110].”
BackgroundMicroglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110 · cited 2×
“However, it is speculated that initial neurotoxic insult to dopaminergic neurons results in the release of certain factors that activate microglia and convert them from beneficial into harmful [121].”
BackgroundNagase, H., & Woessner, J. F. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.21491 · Cited by 3,912
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 1×
“Besides aging, the most prominent genetic risk factor for developing late onset AD is the presence of apolipoprotein E ε4 allele (APOE ε4) in the genome [173].”
BackgroundNeuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345 · cited 1×
“Aβ deposits are typically surrounded by dystrophic neurites, reactive astrocytes, and activated microglia, forming densecore plaques in the brain parenchyma [158].”
Background
Research works printed but not linked: 4
- 10.1002/(sici)1097-4547(19981001)54:160;68::aid-jnr862;3.0.co;2-f · doi:10.1002/(sici)1097-4547(19981001)54:160;68::aid-jnr862;3.0.co;2-f
- 10.1002/1531-8249(199912)46:660;860::aid-ana862;3.0.co;2-m · doi:10.1002/1531-8249(199912)46:660;860::aid-ana862;3.0.co;2-m
- Goldenberg M. M., 2012, Multiple sclerosis review, P & T, 37, 175
- 10.1523/JNEUROSCI.0967-12.2012 · DOI · Paper page
Cited by
The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases
Cabral-Pacheco, G. A., Garza-Veloz, I., Castruita-De la Rosa, C., Ramirez-Acuña, J. M., Perez-Romero, B. A., Guerrero-Rodriguez, J. F., Martinez-Avila, N., & Martinez-Fierro, M. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249739 · Cited by 1,820
“It has been shown that MMPs participate in a common pathway related to the pathological changes in CNS homeostasis, that is, the accumulation of pro-inflammatory molecules or aggregates of proteins and peptides, leading to the increased permeability of the CNS barrier and, therefore, to cell death [48].”
BackgroundInfluentialde Almeida, L. G. N., Thode, H., Eslambolchi, Y., Chopra, S., Young, D., Gill, S., Devel, L., & Dufour, A. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000349 · Cited by 535
Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing
Boland, B., Yu, W. H., Corti, O., Mollereau, B., Henriques, A., Bezard, E., Pastores, G. M., Rubinsztein, D. C., Nixon, R. A., Duchen, M. R., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.109 · Cited by 558
Chinta, S. J., Woods, G., Demaria, M., Rane, A., Zou, Y., McQuade, A., Rajagopalan, S., Limbad, C., Madden, D. T., Campisi, J., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2017.12.092 · Cited by 530
“, 2010); SASP factors have been shown to disrupt tissue structure and function (Brkic et al., 2015).”
BackgroundThe vascular basement membrane in the healthy and pathological brain
Thomsen, M. S., Routhe, L. J., & Moos, T. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17722436 · Cited by 490
“MMPs, a family of zinc endopeptidases, are produced in a latent form and contain a pro-peptide responsible for maintaining the latent form of MMP and a hemopexin-like domain, which can be recognized by tissue inhibitor of metalloproteinases (TIMPs).(96) The activity of these protease systems is highly regulated and de…”
BackgroundThe Infectious Etiology of Alzheimer’s Disease
Sochocka, M., Zwolińska, K., & Leszek, J. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170313122937 · Cited by 399
“MMPs are induced endogenously by the amyloid molecules in blood vessels, astrocytes and microglia [25, 26].”
BackgroundScheau, C., Badarau, I. A., Costache, R., Caruntu, C., Mihai, G. L., Didilescu, A. C., Constantin, C., & Neagu, M. (2019) · Analytical Cellular Pathology · doi:10.1155/2019/9423907 · Cited by 367
“MMPs are produced as zymogens (pro-MMPs) that are activated by other enzymes or free radicals through the cysteine switch mechanism [11].”
BackgroundThe role of matrix metalloproteinases in aging: Tissue remodeling and beyond
Freitas-Rodríguez, S., Folgueras, A. R., & López-Otín, C. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.05.007 · Cited by 354
“In fact, MT5-MMP (MMP-24) regulates neural stem cell quiescence through the cleavage of the anchoring protein N-cadherin, which is essential for the maintenance of the stem cell niche architecture [94].”
BackgroundInfluentialRedox control of senescence and age-related disease.
Chandrasekaran, A., Idelchik, M. D. P. S., & Melendez, J. A. (2017) · Redox Biology · doi:10.1016/j.redox.2016.11.005 · Cited by 360
“physiological conditions, but can be abnormally high in several ageassociated pathologies [132,137].”
BackgroundMetalloproteinases and Their Inhibitors: Potential for the Development of New Therapeutics
Raeeszadeh-Sarmazdeh, M., Do, L., & Hritz, B. (2020) · Cells · doi:10.3390/cells9051313 · Cited by 324
“MMP‐9 and its endogenous activator, MMP‐3, were shown to contributes to AD pathology are associated with synaptopathic neurodegenerative disorders [9,111,116,117].”
BackgroundMatrix Metalloproteinases: A challenging paradigm of cancer management
Alaseem, A., Alhazzani, K., Dondapati, P., Alobid, S., Bishayee, A., & Rathinavelu, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.008 · Cited by 232
Next generation matrix metalloproteinase inhibitors — Novel strategies bring new prospects
Levin, M., Udi, Y., Solomonov, I., & Sagi, I. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.06.009 · Cited by 186
The choroid plexus-cerebrospinal fluid interface in Alzheimer′s disease: more than just a barrier
Vandenbroucke, R., Balusu, S., Brkic, M., & Libert, C. (2016) · Neural Regeneration Research · doi:10.4103/1673-5374.180372 · Cited by 118
Self-citationCounteracting the effects of TNF receptor‐1 has therapeutic potential in Alzheimer's disease
Steeland, S., Gorlé, N., Vandendriessche, C., Balusu, S., Brkic, M., Van Cauwenberghe, C., Van Imschoot, G., Van Wonterghem, E., De Rycke, R., Kremer, A., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708300 · Cited by 121
“Given that disruption of the blood – CSF barrier has been linked to increased activity of matrix metalloproteinases (MMPs) in the choroid plexus (Brkic et al , 2015b), we investigated their expression 6 h after icv injection of A b O. Expression of both Mmp3 and Mmp8 in the choroid plexus was significantly increased a…”
InfluentialSelf-citationKey Aging-Associated Alterations in Primary Microglia Response to Beta-Amyloid Stimulation
Caldeira, C., Cunha, C., Vaz, A. R., Falcão, A. S., Barateiro, A., Seixas, E., Fernandes, A., & Brites, D. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00277 · Cited by 117
Recent advances in the mechanisms of neuroinflammation and their roles in neurodegeneration
Niranjan, R. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.07.003 · Cited by 123
“In fact, MMPs are involved in the second step of neuroinflammation (Brkic et al., 2015; FlorczakRzepka et al., 2012; Liu et al., 2013).”
BackgroundTewari, B. P., Chaunsali, L., Prim, C. E., & Sontheimer, H. W. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.1022754 · Cited by 130
“MMP-2, or gelatinase A, is expressed by both neurons and glial cells; however, astrocytes appear to be the major source (Dzwonek et al., 2004; Brkic et al., 2015).”
BackgroundMatrix Metalloproteinases as New Targets in Alzheimer’s Disease: Opportunities and Challenges
Zipfel, P., Rochais, C., Baranger, K., Rivera, S., & Dallemagne, P. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00352 · Cited by 94
Roles of Matrix Metalloproteinases in Cutaneous Wound Healing
Nguyen, T. T., Mobashery, S., & Chang, M. (2016) · InTech eBooks · doi:10.5772/64611 · Cited by 110
“The pathological outcomes of MMP dysregulation have been the subject of many review articles [8, 10, 75, 76].”
BackgroundSex differences in the blood–brain barrier and neurodegenerative diseases
Weber, C. M., & Clyne, A. M. (2021) · APL Bioengineering · doi:10.1063/5.0035610 · Cited by 91
Blood–Brain Barrier and Neurodegenerative Diseases—Modeling with iPSC-Derived Brain Cells
Wu, Y.-C., Sonninen, T.-M., Peltonen, S., Koistinaho, J., & Lehtonen, Š. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147710 · Cited by 89
“Furthermore, increased expression and subsequent activation of MMP proteins are reported to activate the immune response and contribute to neuroinflammation [75].”
BackgroundDhanda, S., & Sandhir, R. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0521-7 · Cited by 94
Luo, F., Tran, A. P., Xin, L., Sanapala, C., Lang, B. T., Silver, J., & Yang, Y. (2018) · Nature Communications · doi:10.1038/s41467-018-06505-6 · Cited by 79
Modeling Neurodegenerative Microenvironment Using Cortical Organoids Derived from Human Stem Cells
Yan, Y., Song, L., Bejoy, J., Zhao, J., Kanekiyo, T., Bu, G., Zhou, Y., & Li, Y. (2018) · Tissue Engineering Part A · doi:10.1089/ten.tea.2017.0423 · Cited by 87
Wołosowicz, M., Prokopiuk, S., & Kaminski, T. W. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17111425 · Cited by 90
“In neurodegenerative diseases such as Alzheimer’s and Parkinson’s, persistent MMP-9 activity induces low-grade BBB leakage, facilitating accumulation of inflammatory mediators and neurotoxic proteins that exacerbate neuronal damage and accelerate disease progression [33].”
Riaz, B., & Sohn, S. (2023) · Cells · doi:10.3390/cells12222621 · Cited by 82
The restorative role of annexin A1 at the blood–brain barrier
McArthur, S., Loiola, R. A., Maggioli, E., Errede, M., Virgintino, D., & Solito, E. (2016) · Fluids and Barriers of the CNS · doi:10.1186/s12987-016-0043-0 · Cited by 80
“The contribution this molecular component of the NVU plays in maintaining BBB integrity has not been fully clarified, but enzymes such as the matrix metalloproteinases that disrupt its structure have been implicated in inappropriate immune cell or parasite entry into the brain [20, 21] and in oedema and haemorrhage du…”
BackgroundAddressing Blood–Brain Barrier Impairment in Alzheimer’s Disease
Sharma, C., Woo, H., & Kim, S. R. (2022) · Biomedicines · doi:10.3390/biomedicines10040742 · Cited by 68
Global alterations to the choroid plexus blood-CSF barrier in amyotrophic lateral sclerosis
Saul, J., Hutchins, E., Reiman, R., Saul, M., Ostrow, L. W., Harris, B. T., Van Keuren-Jensen, K., Bowser, R., & Bakkar, N. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00968-9 · Cited by 69
Matrix metalloproteinases – From the cleavage data to the prediction tools and beyond
Cieplak, P., & Strongin, A. Y. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.03.010 · Cited by 63
Radioprotective effect of Date syrup on radiation- induced damage in Rats
Abou‐Zeid, S. M., El‐Bialy, B. E., El-Borai, N. B., AbuBakr, H. O., & Elhadary, A. M. A. (2018) · Scientific Reports · doi:10.1038/s41598-018-25586-3 · Cited by 62
“Likewise, matrix metalloproteinases (MMPs); family of calcium-dependent, zinc-containing endopeptidases that includes stromelysins (1,3) collagenases (1,3,8), gelatinases (2,9) and membrane type1 MMP8 are induced by proinflammatory cytokines such as tumor necrotic factor alpha (TNF-α), interleukin 1β (IL-1β) and sever…”
Benvenuti, L., D'Antongiovanni, V., Pellegrini, C., Antonioli, L., Bernardini, N., Blandizzi, C., & Fornai, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239199 · Cited by 55
“This glial response under pathological conditions, known as “reactive gliosis”, usually triggers a broad spectrum of alterations, including TLRs activation [30,31], altered expression and release of several glia-related proteins and enzymes, such as GFAP, S100B, inducible nitric oxide synthase (iNOS), and matrix metal…”
BackgroundMatrix Metalloproteinase-9 as an Important Contributor to the Pathophysiology of Depression
Li, H., Sheng, Z., Khan, S., Zhang, R., Liu, Y., Zhang, Y., Yong, V. W., & Xue, M. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.861843 · Cited by 68
Importance of Metalloproteinase 8 (MMP-8) in the Diagnosis of Periodontitis
Zalewska, E. A., Ławicka, R., Grygorczuk, P., Nowosielska, M., Kicman, A., & Ławicki, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052721 · Cited by 54
“The dysregulation of MMPs is associated with the development of cardiovascular, respiratory [13,51,53,68], nervous [14,51,69,70], and excretory diseases [51,71], among others.”
BackgroundTissue specific microenvironments: a key tool for tissue engineering and regenerative medicine
Sachs, P. C., Mollica, P. A., & Bruno, R. D. (2017) · Journal of Biological Engineering · doi:10.1186/s13036-017-0077-0 · Cited by 56
“A number of studies have identified possible mechanisms of ECM degradation in neurodegenerative disorders, including matrix metalloproteinase activation [115], decreases in tissue inhibitors of metalloproteinase expression [116], aberrant expression of tissue plasminogen activators [117], and insult-induced neuro-infl…”
BackgroundMMP-mediated modulation of ECM environment during axonal growth and NMJ development
Chan, Z. C.-K., Oentaryo, M. J., & Lee, C. W. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.134822 · Cited by 53
The Link Between Matrix Metalloproteinases and Alzheimer’s Disease Pathophysiology
Radošinská, D., & Radošinská, J. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04315-0 · Cited by 55
Lee, E.-J., Park, J., Lee, Y., Kim, D.-Y., Kang, J. L., & Kim, H.-S. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1363-6 · Cited by 51
The Diverse Roles of TIMP-3: Insights into Degenerative Diseases of the Senescent Retina and Brain
Dewing, J. M., Carare, R. O., Lotery, A. J., & Ratnayaka, J. A. (2019) · Cells · doi:10.3390/cells9010039 · Cited by 60
“Furthermore, expression of MMPs are increased in neurodegenerative disorders including AD [34].”
BackgroundCiccone, L., Vandooren, J., Nencetti, S., & Orlandini, E. (2021) · Pharmaceuticals · doi:10.3390/ph14020086 · Cited by 47
“Interesting, both the beneficial and detrimental functions of MMPs in neurodegeneration and neuroinflammation have been described [17].”
BackgroundNeuroprotective potential of isothiocyanates in an in vitro model of neuroinflammation
Latronico, T., Larocca, M., Milella, S., Fasano, A., Rossano, R., & Liuzzi, G. M. (2020) · Inflammopharmacology · doi:10.1007/s10787-020-00772-w · Cited by 46
Ye, Z., Wei, J., Zhan, C., & Hou, J. L. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.917587 · Cited by 53
“release of the active form of TGF-β1, potentially creating a positive feedback loop that exacerbates BNB permeability (Brkic et al., 2015).”
BackgroundHong, C., Hu, H., Chan, L., & Bai, C. (2018) · Clinical Epidemiology · doi:10.2147/clep.s163493 · Cited by 46
“23 The symptoms of PD are not limited to motor dysfunctions but also extend to nonmotor dysfunctions.”
Motyl, J. A., Wencel, P. L., Cieślik, M., Strosznajder, R. P., & Strosznajder, J. B. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-0317-1 · Cited by 51
Overview of MMP Biology and Gene Associations in Human Diseases
Djurić, T., & Živković, M. (2017) · InTech eBooks · doi:10.5772/intechopen.70265 · Cited by 49
Blood-brain barrier and innate immunity in the pathogenesis of Alzheimer's disease
Šimić, G., Španić, E., Horvat, L. L., & Hof, P. R. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.06.003 · Cited by 41
Recent insights into natural product inhibitors of matrix metalloproteinases
Kumar, G. B., Nair, B. G., Perry, J. J. P., & Martin, D. B. C. (2019) · MedChemComm · doi:10.1039/c9md00165d · Cited by 40
Cathepsins in neuronal plasticity
Silver, J., & Tran, A. P. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.286948 · Cited by 42
“Thus, the inflammatory processes incurred by traumatic spinal cord injury initiates a “protease storm” where promiscuous and non-regulated protease activity is unleashed to instigate tissue damage and further the inflammatory cascade (Noble et al., 2002; Veeravalli et al., 2012; Brkic et al., 2015).”
BackgroundHarnessing cerebral organoids for Alzheimer's disease research
Bubnys, A., & Tsai, L. (2021) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2021.10.003 · Cited by 44
Yıldız, M. O., Çelik, H., Çağlayan, C., Genç, A., Doğan, T., & Satıcı, E. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-00945-2 · Cited by 40
“In pathophysiological conditions, aberrant expression of MMPs induces chronic inflammation and leads to the progression of neurodegenerative diseases (Brkic et al. 2015).”
BackgroundFalcão, A. S., Carvalho, L. A. R., Lidónio, G., Vaz, A. R., Lucas, S. D., Moreira, R., & Brites, D. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00250 · Cited by 39
Kaminari, A., Tsilibary, E. C., & Tzinia, A. K. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180035 · Cited by 42
“MMP-9,inparticular, isextensivelystudiedastoitscrucialroleintheCNS andinthedevelopmentofneurodegenerativediseases [21,22].”
Tuna, G., Yener, G., Oktay, G., İşlekel, H., & Kirkali, F. G. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180752 · Cited by 43
Serifova, X., Ugarte-Berzal, E., Opdenakker, G., & Vandooren, J. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03338-4 · Cited by 41
Rotenone induced neurodegeneration is mediated via cytoskeleton degradation and necroptosis
Roy, T., Chatterjee, A., & Swarnakar, S. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2022.119417 · Cited by 37
MMP-3 Deficiency Alleviates Endotoxin-Induced Acute Inflammation in the Posterior Eye Segment
Hove, I. V., Lefevere, E., Groef, L. D., Sergeys, J., Salinas‐Navarro, M., Libert, C., Vandenbroucke, R. E., & Moons, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111825 · Cited by 37
Self-citationNovel matrix metalloproteinase inhibitors: an updated patent review (2014 - 2020)
Lenci, E., Cosottini, L., & Trabocchi, A. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1881481 · Cited by 38
Wang, T., Yin, Y., Jiang, X., Ruan, Y., Xu, J., Hu, X., Li, T., Chu, L., & Li, L. (2023) · Scientific Reports · doi:10.1038/s41598-023-41101-9 · Cited by 36
Wu, J., Yang, J., Lu, X., Jin, C., Wu, S., Zhang, L., Hu, X., Ma, H., & Cai, Y. (2018) · Biological Trace Element Research · doi:10.1007/s12011-018-1402-2 · Cited by 33
Maugeri, G., D’Amico, A. G., Rasà, D. M., Federico, C., Saccone, S., Morello, G., Cognata, V. L., Cavallaro, S., & D’Agata, V. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27328 · Cited by 33
Zhao, C., Bai, X., Wen, A., Wang, J., & Ding, Y. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107527 · Cited by 32
The MMP-2/TIMP-2 System in Alzheimer Disease
Wang, H., Huang, L., Wu, L., Lan, J., Feng, X., Li, P., & Peng, Y. (2020) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527319666200812223007 · Cited by 33
Plantone, D., Inglese, M., Salvetti, M., & Koudriavtseva, T. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2018.01175 · Cited by 35
Seguella, L., Capuano, R., Sarnelli, G., & Esposito, G. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1612744 · Cited by 35
Naphade, S. B., Embusch, A., Madushani, K. L., Ring, K. L., & Ellerby, L. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00736 · Cited by 31
“However, multiple MMPs are expressed in all cell types throughout the body, with some having crucial multifaceted roles in normal physiology (Brkic et al., 2015), thereby emphasizing the need for developing very specific MMP inhibitors.”
BackgroundDifferential Expression and miRNA–Gene Interactions in Early and Late Mild Cognitive Impairment
Brito, L. M., Ribeiro‐dos‐Santos, Â., Vidal, A. F., & de Araújo, G. S. (2020) · Biology · doi:10.3390/biology9090251 · Cited by 33
Bejoy, J., Song, L., Wang, Z., Sang, Q. A., Zhou, Y., & Li, Y. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b00021 · Cited by 32
The TIMP protein family: diverse roles in pathophysiology
Coates-Park, S., Rich, J. A., Stetler‐Stevenson, W. G., & Peeney, D. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00699.2023 · Cited by 36
Chua, S. K. K., Saffari, S. E., Lee, S. J. Y., & Tan, E. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-223291 · Cited by 35
“Activation of MMPs causes ECM degradation and Blood-Brain-Barrier leakage, which could facilitate microglial activation and dopaminergic neurodegeneration [39].”
BackgroundEndogenous Mechanisms of Neuroprotection: To Boost or Not to Be
Marmolejo-Martínez-Artesero, S., Casas, C., & Romeo-Guitart, D. (2021) · Cells · doi:10.3390/cells10020370 · Cited by 30
Ortega, J. A., de Aguiar, G. P. S., Chandravanshi, P., Levy, N., Engel, E., & Álvarez, Z. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1962 · Cited by 28
Zhang, F., Liu, E., Radaic, A., Yu, X., Yang, S., Yu, C., Xiao, S., & Ye, C. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.07.165 · Cited by 29
Morello, G., Spampinato, A. G., Conforti, F. L., D’Agata, V., & Cavallaro, S. (2017) · Journal of Molecular Neuroscience · doi:10.1007/s12031-017-0898-9 · Cited by 28
“In agreement to these evidences, deregulation of MMP system is thought to contribute strongly to the development of many neurodegenerative diseases, including ALS (Brkic et al. 2015; NiebrojDobosz et al. 2010).”
BackgroundLee, E.-J., Choi, M. J., Lee, G., Gaire, B. P., Choi, J. W., & Kim, H.-S. (2017) · Oncotarget · doi:10.18632/oncotarget.20207 · Cited by 27
Ren, X., Wang, G., Zhang, X., Wang, Q.-Q., & Peng, Z.-P. (2020) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-020-3087-6 · Cited by 24
Translatomic analysis of regenerating and degenerating spinal motor neurons in injury and ALS
Shadrach, J. L., Stansberry, W. M., Milen, A. M., Ives, R. E., Fogarty, E. A., Antonellis, A., & Pierchala, B. A. (2021) · iScience · doi:10.1016/j.isci.2021.102700 · Cited by 28
“Matrix metalloproteinases (MMPs) are a large family of zinc-dependent proteases that degrade basement membrane and extracellular matrix components and function in immune processes by cleaving growth factors, chemokines, and cytokines (Brkic et al., 2015).”
BackgroundGanguly, K., Adhikary, K., Acharjee, A., Acharjee, P., Trigun, S. K., Mutlaq, A. S., Ashique, S., Yasmin, S., Alshahrani, A. M., & Ansari, M. Y. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.135967 · Cited by 26
Tightening the retinal glia limitans attenuates neuroinflammation after optic nerve injury
Lefevere, E., Salinas‐Navarro, M., Andries, L., Noterdaeme, L., Etienne, I., Wonterghem, E. V., Vinckier, S., Davis, B. M., Bergen, T. V., Hove, I. V., et al. (2020) · Glia · doi:10.1002/glia.23875 · Cited by 24
Self-citationKoca, S., Kiris, İ., Şahin, Ş., Çınar, N., Karşıdağ, S., Hanağası, H. A., Yıldız, G. B., & Baykal, A. T. (2022) · Neuroscience Letters · doi:10.1016/j.neulet.2022.136799 · Cited by 24
Dai, L., Mugaanyi, J., Cai, X., Dong, M., Lu, C., & Lu, C. (2022) · Scientific Reports · doi:10.1038/s41598-022-17954-x · Cited by 27
Senthilkumar, S., Venugopal, C., Parveen, S., Shobha, K., Rai, K. S., Kutty, B. M., & Dhanushkodi, A. (2020) · NeuroToxicology · doi:10.1016/j.neuro.2020.08.006 · Cited by 23
Ligand-based Design of Anticancer MMP2 Inhibitors: a Review
Sanyal, S. K., Amin, S. A., Adhikari, N., & Jha, T. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0262 · Cited by 22
SoukhakLari, R., Moezi, L., Pirsalami, F., & Moosavi, M. (2018) · Journal of Molecular Neuroscience · doi:10.1007/s12031-018-1104-4 · Cited by 21
Pullen, N., Pickford, A. R., Perry, M. M., Jaworski, D. M., Loveson, K. F., Arthur, D., Holliday, J., Meter, T. E. V., Peckham, R., Younas, W., et al. (2018) · Metalloproteinases In Medicine · doi:10.2147/mnm.s105123 · Cited by 24
Matrix metalloproteinase-9 (MMP-9): A macromolecular mediator in CNS infections: A review
Mubarak, M. M., Baba, I. A., Wani, Z. A., Kantroo, H. A., & Ahmad, Z. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.143902 · Cited by 24
Plasma MMP-9/TIMP-1 ratio serves as a novel potential biomarker in Alzheimer’s disease
Liu, J., Li, X., & Qu, J. (2023) · Neuroreport · doi:10.1097/wnr.0000000000001952 · Cited by 22
Falquetto, B., Thieme, K., Malta, M. B., Rocha, K. C. E., Cavalleri, M. T., Potje, S. R., Antoniali, C., Rodrigues, A. C., Munhoz, C. D., Moreira, T. S., et al. (2020) · The Journal of Physiology · doi:10.1113/jp279791 · Cited by 22
“Unlike what occurs in the SN neurons, in the present study, we did not observe signs of BBB rupture in the medullary respiratory regions based on the following evidence: (i) lack of extravasation of Evans Blue, a substance that normally should not cross the barrier, in the encephalic parenchyma (Yao & May, 2013); (ii)…”
BackgroundMethodFreitas, A., Aroso, M., Rocha, S., Ferreira, R. M., Vitorino, R. M. P., & Gómez-Lázaro, M. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15316 · Cited by 22
“Moreover, a common alteration found in these three diseases at the ECM level was the change on the expression levels of matrix metalloproteases (MMPs) (Annese et al., 2015; Brkic et al., 2015), which are key players for matrix remodeling (Bonneh- Barkay & Wiley, 2009).”
BackgroundHristovska, I., Binette, A. P., Kumar, A., Wennström, M., Gaiteri, C., Karlsson, L., Strandberg, O. T., Janelidze, S., van Westen, D., Stomrud, E., et al. (2026) · Nature Aging · doi:10.1038/s43587-026-01081-7 · Cited by 26
“MMPs can influence cSVD by proteolyzing cerebrovascular basement membranes, altering tight junctions and activating bioactive molecules like clotting factors and signaling proteins 46 .”
NFL strongly correlates with TNF-R1 in the plasma of AD patients, but not with cognitive decline
Delaby, C., Julian, A. G., Page, G., Ragot, S., Lehmann, S., & Paccalin, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-89749-5 · Cited by 19
Kicman, A., Niczyporuk, M., Kulesza, M., Motyka, J., & Ławicki, S. (2022) · Cancer Management and Research · doi:10.2147/cmar.s385658 · Cited by 20
Inhibition of MMP-2 and MMP-9 attenuates surgery-induced cognitive impairment in aged mice
Ji, Y., Huang, W., Chen, Y., Zhang, X., Wu, F., Tang, W., Lu, Z., & Huang, C. (2023) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2023.110810 · Cited by 22
“MMP-2 and MMP-9 have been detected in human and rodent astrocytes and microglia (Brkic et al., 2015; Song and Dityatev, 2018).”
BackgroundIslam, Y., Khalid, A., Pluchino, S., Sivakumaran, M., Teixidò, M., Leach, A. G., Fatokun, A. A., Downing, J., Coxon, C. R., & Ehtezazi, T. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.06.021 · Cited by 21
Dolmatov, I. Y., Nizhnichenko, V. A., & Dolmatova, L. S. (2021) · Cells · doi:10.3390/cells10092331 · Cited by 22
“Their activation is possibly induced by high levels of reactive oxygen species (ROS) [71,129], which are produced by echinoderm cells in response to damage [19].”
BackgroundKuliczkowski, W., Radomski, M. W., Gąsior, M., Urbaniak, J., Kaczmarski, J., Mysiak, A., Negrusz‐Kawecka, M., & Bil‐Lula, I. (2017) · BioMed Research International · doi:10.1155/2017/9352015 · Cited by 20
“level in normal adult tissue turnovers such as reproduction [5, 6], development [7], tissue repair [8], or immune response [9, 10] and are upregulated during pathological processes including inflammation [11], autoimmune diseases [12], neurogenerative disorders [13], tumor invasion and metastasis [14, 15], and heart i…”
BackgroundDiagnostic biomarkers of dilated cardiomyopathy
Moeinafshar, A., Yazdanpanah, N., & Rezaei, N. (2021) · Immunobiology · doi:10.1016/j.imbio.2021.152153 · Cited by 20
Matrix metalloproteinases are associated with brain atrophy in cognitively unimpaired individuals
Aksnes, M., Capogna, E., Dídac Vidal-piñeiro, A., Chaudhry, F. A., Myrstad, M., Idland, A., Halaas, N. B., Dakhil, S., Blennow, K., Zetterberg, H., et al. (2023) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.05.012 · Cited by 18
“Changes in the balance between MMPs and TIMPs have also been linked to age-related vascular diseases and increased neuroinflammation in the aging brain (Brkic et al., 2015).”
Unraveling the role of proteins in dementia: insights from two UK cohorts with causal evidence
Gong, J., Williams, D. M., Scholes, S., Assaad, S., Bu, F., Hayat, S. A., Zaninotto, P., & Steptoe, A. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf097 · Cited by 19
“72,73 MMPs play important roles in cell proliferation and death, neuroinflammation, neurodegeneration and glial reactivity 74 and are linked to their proteolytic disruption action on the blood-brain barrier.”
Wang, B., Yang, L., & You, C. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s285179 · Cited by 17
“MMP-2 may play a role in Alzheimer’s disease (AD) pathology.(37) An MMP-2 inhibition prevented”
BackgroundZhu, M., Yang, M. S., Yang, Q., Liu, W., Geng, H., Li, P., Wang, L., Ge, R., Ji, L., Cui, S., et al. (2020) · BioMed Research International · doi:10.1155/2020/9204708 · Cited by 17
Metadata
- Authors
- Brkic, M., Balusu, S., Libert, C., & Vandenbroucke, R. E.
- Affiliations
- Ghent University (BE)
- Corresponding author
- Vandenbroucke, Roosmarijn E.
- Venue
- Mediators of Inflammation
- Publisher
- Wiley
- Published
- 2015-01
- Volume
- 2015
- Issue
- 1
- Pages
- 620581-620581
- ISSN
- 0962-9351 (ISSN-L)
- 1466-1861
- PMC
- PMC4619970
- OpenAlex
- W2165521823
- Cited by
- 205
- References
- 310
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 19 · 2023: 12 · 2022: 24 · 2021: 36 · 2020: 28 · 2019: 13 · 2018: 24 · 2017: 22 · 2016: 8
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Mediators of Inflammation (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministry of Education, Science and Technological Development of the Republic of Serbia (ON173056)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- matrix metalloproteinases, neurodegenerative diseases, neuroinflammation, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, matrix metalloproteinase inhibition, therapeutic target
- MeSH terms
- Alzheimer Disease, Amyotrophic Lateral Sclerosis, Animals, Humans, Huntington Disease, Inflammation, Multiple Sclerosis, Parkinson Disease, Biomarkers, Gene Expression Regulation, Enzymologic, Neurodegenerative Diseases, Matrix Metalloproteinases, Neurogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.